Upgrade to SI Premium - Free Trial

Anavex Life Sciences (AVXL) 31-Week Data Shows Anavex 2-73 Continues to be Well Tolerated - FBR

July 25, 2016 8:47 AM
FBR Capital analyst Christopher James reiterated an Outperform rating and $10 price target on Anavex Life Sciences (NASDAQ: AVXL) after ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments FDA

Next Articles